Company Overview

Our primary mission is to create new medical technologies and businesses which improve the lives of patients and create value for our customers and shareholders. 

Founded in 1995, ExploraMed is a venture-backed medical technology incubation company dedicated to the identification, creation and development of new medical device businesses. ExploraMed provides expertise, intellectual property and capital to new ideas which match certain key fundamental criteria and focuses on developing these opportunities in an efficient and timely manner. 

Partnered with New Enterprise Associates and several key business and clinical leaders from the medical technology industry, ExploraMed has the capability to leverage substantial financial and intellectual resources to accelerate the creation and establishment of new medical technologies, procedures and companies.  

ExploraMed I created two medical device companies, EndoMatrix Inc., and TransVascular Inc. EndoMatrix was created to develop a novel approach towards tissue bulking in incontinence and GI Reflux, and was acquired by C.R. Bard, Inc. in 1997. TransVascular, Inc. was created to develop several novel revascularization technologies including percutaneous coronary and peripheral bypass and cell injection technologies for cardiac regeneration, and was acquired by Medtronic, Inc. in 2003. 

ExploraMed II, founded in 2004, was slated to create two to three new companies and has thus far produced two new businesses, Acclarent Inc.. and NeoTract Inc. .  Acclarent, Inc., a company focused on developing several new technologies in the field of ENT, exited the incubator in January 2005.  Acclarent, Inc. is currently commercializing their technology and has received over $42MM in venture funding from Versant Ventures, NEA and others. NeoTract, Inc., ExploraMed’s most recent spinout, exited ExploraMed II in February 2006 and raising over $13MM in venture funding from NEA and others. 

ExploraMed III was launched in 2006 and has already spun off it's first company, Vibrynt, Inc. ExploraMed III expects to create one or two more companies over the next three years.